NCT05633524

Brief Summary

Sjögren's syndrome (SS) is an autoimmune disorder characterized by chronic salivary and lacrimal gland dysfunction leading to dry mouth (xerostomia) and dry eye (xerophthalmia) sensation (1). Although dry mouth and dry eye are the main symptoms, the disease may influence many organs and systems. Diagnosis is made with ocular surface staining scores, anti-SS-A/SS-B auto-antibody positivity, and minor salivary gland biopsy (2). The Complete blood count (CBC) is a simple, inexpensive, accessible, and routinely used laboratory parameter that can be linked to oxidative stress, inflammation and microvascular flow resistance. Parameters include NLR and PLR values may be calculated by using CBC parameters (3). Neutrophil/lymphocyte ratio is used as an inflammatory marker in the diagnosis and prognosis of many cardiovascular diseases, malignancies, and infections (4-6). Peripheral inflammatory biomarkers of hematologic indices had been suggested by numerous studies to play a role during SS onset and progression.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
89

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 29, 2020

Completed
2.1 years until next milestone

First Submitted

Initial submission to the registry

November 21, 2022

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 21, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 21, 2022

Completed
10 days until next milestone

First Posted

Study publicly available on registry

December 1, 2022

Completed
Last Updated

December 2, 2022

Status Verified

November 1, 2022

Enrollment Period

2.1 years

First QC Date

November 21, 2022

Last Update Submit

November 30, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • HRR

    hemoglobin-to-red cell distribution width ratio

    change from baseline at 24 months

Study Arms (2)

89 SS patients

The medical records were analyzed retrospectively about the 89 patients with first onset of SS (SS group)

Other: blood sample analysis

89 healthy control subjects

The medical records were analyzed retrospectively about the 89 age- and gender-matched individuals (Control group) who presented with normal control.

Other: blood sample analysis

Interventions

All subjects went through a routine ocular examination, and the peripheral venous blood samples were collected and analyzed

89 SS patients89 healthy control subjects

Eligibility Criteria

Age45 Years - 67 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

A total of 89 SS patients and 89 age- and gender-matched healthy subjects were included. Eighty-nine primary SS patients who met the 2012 American College of Rheumatology (ACR-2012) classification criteria and 89 healthy controls were enrolled.

You may qualify if:

  • must meet the 2012 American College of Rheumatology classification criteria,
  • without systemic diseases, such as hypertension, diabetes, cardiovascular diseases, and chronic obstructive pulmonary disease,
  • without malignant tumors,
  • without renal failure,
  • without liver diseases,
  • without anemia,
  • without smoking and alcohol consumption,
  • without active infection,
  • without other autoimmune diseases,
  • without medicine usage that could influence the blood coagulation state,
  • without a history of concurrent ocular diseases or trauma,
  • without any surgery within three months.

You may not qualify if:

  • systemic diseases, such as hypertension, diabetes, cardiovascular diseases, and chronic obstructive pulmonary disease,
  • malignant tumor,
  • renal failure,
  • liver diseases,
  • anemia,
  • smoking and alcohol consumption,
  • active infection,
  • other autoimmune diseases,
  • medicine usage that could influence the blood coagulation state,
  • a history of concurrent ocular diseases or trauma,
  • any surgery within three months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tianjin Eye Hospital

Tianjin, Tianjin Municipality, China

Location

Related Publications (3)

  • Psianou K, Panagoulias I, Papanastasiou AD, de Lastic AL, Rodi M, Spantidea PI, Degn SE, Georgiou P, Mouzaki A. Clinical and immunological parameters of Sjogren's syndrome. Autoimmun Rev. 2018 Oct;17(10):1053-1064. doi: 10.1016/j.autrev.2018.05.005. Epub 2018 Aug 10.

  • Yildiz F, Gokmen O. Haematologic indices and disease activity index in primary Sjogren's syndrome. Int J Clin Pract. 2021 Mar;75(3):e13992. doi: 10.1111/ijcp.13992. Epub 2021 Jan 19.

  • Hu ZD, Sun Y, Guo J, Huang YL, Qin BD, Gao Q, Qin Q, Deng AM, Zhong RQ. Red blood cell distribution width and neutrophil/lymphocyte ratio are positively correlated with disease activity in primary Sjogren's syndrome. Clin Biochem. 2014 Dec;47(18):287-90. doi: 10.1016/j.clinbiochem.2014.08.022. Epub 2014 Sep 7.

MeSH Terms

Conditions

Sjogren's Syndrome

Condition Hierarchy (Ancestors)

Arthritis, RheumatoidArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesXerostomiaSalivary Gland DiseasesMouth DiseasesStomatognathic DiseasesDry Eye SyndromesLacrimal Apparatus DiseasesEye DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Yan Wang

    Tianjin Eye Hospital and Eye Institute, Nankai University Affiliated Eye Hospital

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 21, 2022

First Posted

December 1, 2022

Study Start

October 29, 2020

Primary Completion

November 21, 2022

Study Completion

November 21, 2022

Last Updated

December 2, 2022

Record last verified: 2022-11

Locations